Wednesday, 5 October 2016

AstraZeneca licenses respiratory drug to Insmed

(Reuters) - Drugmaker Insmed Inc said it on Wednesday it had bought the rights to an experimental early-stage respiratory drug from Britain's AstraZeneca Plc in a deal worth $150 million.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)